首页> 外文期刊>Acta gastro-enterologica Belgica >Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy.
【24h】

Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy.

机译:原发性十二指肠滤泡性淋巴瘤:联合放射免疫治疗后6年完全缓解。

获取原文
获取原文并翻译 | 示例
           

摘要

Primary gastrointestinal lymphoma (PGL) is known to account for 40% of all extranodal non-Hodgkin's lymphomas (NHLs) and between 4% to 12% of all NHLs. The small intestine is the site of presentation in 20-30% of cases, with the terminal ileum usually involved. Duodenal localizations have always been thought to be rare, but are presently growing in incidence. We herein report on a case of Stage IV primary duodenal FCL, located to the second portion of the duodenum with concomitant minimal bone marrow involvement. The patient was frontline approached with a conservative combined modality treatment consisting of 4 weekly infusions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duodenal portion. Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity.
机译:已知原发性胃肠道淋巴瘤(PGL)占所有结外非霍奇金淋巴瘤(NHL)的40%,占所有NHL的4%至12%。小肠是20-30%病例的表现部位,回肠末端通常累及。十二指肠定位一直被认为是罕见的,但目前发病率正在上升。我们在此报告了IV期原发性十二指肠FCL的病例,该病例位于十二指肠的第二部分,伴有最小的骨髓累及。对该患者进行了一线保守治疗,包括每周4次输注针对B细胞表面抗原CD-20的嵌合人鼠IgG1单克隆抗体,利妥昔单抗(375 mg / m2)和巩固3D保形外部疗法放疗,将总剂量为36 Gy的放射线照射分为十二个十二指肠部分。治疗结束六年后,患者没有疾病,也没有与治疗相关的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号